Literature DB >> 17574104

Aspirin esterase activity - Evidence for skewed distribution in healthy volunteers.

G I Adebayo1, J Williams, S Healy.   

Abstract

BACKGROUND: Aspirin, with its analgesic, anti-inflammatory, antipyretic, and anti-platelet actions, is one of the most frequently used drugs. Although its use as prophylaxis against thromboembolism is well established, an optimal dose, conferring maximal anti-platelet action without increased risk of bleeding, remains elusive.
METHOD: We assessed the possible pharmacokinetic contribution to this problem in 107 healthy, non-medicated volunteers. Serum aspirin esterase activity was evaluated at 37 degrees C with 1 mM aspirin as substrate. On the basis of the report that most of aspirin esterase activity is accounted for by pseudocholinesterase, we additionally quantified the activity of this enzyme, with and without dibucaine as an inhibitor, using Ellman's reaction, in 41 of our volunteers.
RESULTS: Aspirin esterase activities in all of our volunteers (33.90 nmol/ml/min to 222.65 nmol/ml/min, median 103.45 nmol/ml/min) showed a continuous and skewed distribution with eight outliers. In the 41 subjects so studied, aspirin esterase activities correlated positively with both pseudocholinesterase activities (Spearman's rho=0.593, p<0.001) and dibucaine numbers (Spearman's rho=0.422, p<0.01).
CONCLUSIONS: Our results support previous observations that the rate of aspirin hydrolysis is not determined by aspirin esterase alone and that other factors are probably involved. Additionally, the skewed distribution of aspirin esterase activities makes a case for its possible contribution to the phenomenon of aspirin resistance.

Entities:  

Year:  2007        PMID: 17574104     DOI: 10.1016/j.ejim.2006.12.004

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  7 in total

Review 1.  Obesity and Altered Aspirin Pharmacology.

Authors:  Nicholas B Norgard
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

2.  Intracellular erythrocyte platelet-activating factor acetylhydrolase I inactivates aspirin in blood.

Authors:  Gang Zhou; Gopal K Marathe; Belinda Willard; Thomas M McIntyre
Journal:  J Biol Chem       Date:  2011-08-15       Impact factor: 5.157

Review 3.  Aspirin and antiplatelet agent resistance: implications for prevention of secondary stroke.

Authors:  David M Greer
Journal:  CNS Drugs       Date:  2010-12       Impact factor: 5.749

4.  Serum cholesterol concentration associated with aspirin esterase activity in older people: preliminary data.

Authors:  Kazuhiko Kotani; Russell Caccavello; Ricardo Hermo; Toshiyuki Yamada; Nobuyuki Taniguchi; Alejandro Gugliucci
Journal:  Int J Med Sci       Date:  2010-05-10       Impact factor: 3.738

5.  Aspirin hydrolysis in plasma is a variable function of butyrylcholinesterase and platelet-activating factor acetylhydrolase 1b2 (PAFAH1b2).

Authors:  Gang Zhou; Gopal K Marathe; Jaana Hartiala; Stanley L Hazen; Hooman Allayee; W H Wilson Tang; Thomas M McIntyre
Journal:  J Biol Chem       Date:  2013-03-18       Impact factor: 5.157

6.  In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method.

Authors:  Michele Dei Cas; Jessica Rizzo; Mariangela Scavone; Eti Femia; Gian Marco Podda; Elena Bossi; Monica Bignotto; Sabrina Caberlon; Marco Cattaneo; Rita Paroni
Journal:  Sci Rep       Date:  2021-05-14       Impact factor: 4.379

7.  Serum aspirin esterase is strongly associated with glucose and lipids in healthy subjects: different association patterns in subjects with type 2 diabetes mellitus.

Authors:  Kazuhiko Kotani; Satoshi Kimura; Tetsu Ebara; Russell Caccavello; Alejandro Gugliucci
Journal:  Diabetol Metab Syndr       Date:  2010-07-27       Impact factor: 3.320

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.